The Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA) welcomes the decision to operate the Medical School at the University of Cyprus come September and is pleased that the various obstacles have been overcome.

KEFEA also congratulates the University of Cyprus for its continuous efforts that have paid off, making the establishment of the Medical School a reality.

“With this decision, Cyprus is making a huge step towards strengthening research and innovation on the island,” said the president of KEFEA Mr. Daan Gijbels, adding that from the first day of operation, the School’s important benefits for Cypriot patients and the wider field of medical research in Cyprus will be evident.

KEFEA, a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA), believes that the proper use of the Medical School will lay the foundations for the creation of a health ecosystem in Cyprus, which will support the development of research and innovation.

Cyprus Association of Research and Development Pharmaceutical Companies (KEFEA) www.kefea.org.cy
The Cyprus Association of Research & Development Pharmaceutical Companies (KEFEA) was founded in 2006 as the representative body of multinational pharmaceutical companies in Cyprus. Its members are GSK, Lilly, MSD, Novartis, Pfizer, Sanofi and Amgen Hellas altogether employing more than 300 people in Cyprus. It is a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). KEFEA’s mission is to provide Cypriots with innovative medicines. Its objectives are to ensure uninterrupted access to medicines at reasonable prices in the Cyprus market, given the acknowledgement of budgetary constraints, provide scientific educational information on diseases and treatments to healthcare providers, ensure that European objectives regarding high healthcare standards are implemented in the Cyprus market, and comply with a common code of ethical practice.